福安藥業(300194.SZ):子公司收到吲哚布芬片的藥品註冊證書
格隆匯2月26日丨福安藥業(300194.SZ)公佈,公司全資子公司福安藥業集團湖北人民製藥有限公司(簡稱“人民製藥”)於近日收到國家藥品監督管理局簽發的吲哚布芬片的藥品註冊證書。
吲哚布芬片適用於動脈硬化引起的缺血性心血管病變、缺血性腦血管病變,靜脈血栓形成。也可用於血液透析時預防血栓形成。根據國家藥品監督管理局數據查詢信息平臺顯示,截止目前,該藥品已有13家企業(含人民製藥)通過一致性評價或視同通過一致性評價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.